162 related articles for article (PubMed ID: 38182303)
21. Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review.
Moris L; Cumberbatch MG; Van den Broeck T; Gandaglia G; Fossati N; Kelly B; Pal R; Briers E; Cornford P; De Santis M; Fanti S; Gillessen S; Grummet JP; Henry AM; Lam TBL; Lardas M; Liew M; Mason MD; Omar MI; Rouvière O; Schoots IG; Tilki D; van den Bergh RCN; van Der Kwast TH; van Der Poel HG; Willemse PM; Yuan CY; Konety B; Dorff T; Jain S; Mottet N; Wiegel T
Eur Urol; 2020 May; 77(5):614-627. PubMed ID: 32146018
[TBL] [Abstract][Full Text] [Related]
22. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
23. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
Lowrance WT; Breau RH; Chou R; Chapin BF; Crispino T; Dreicer R; Jarrard DF; Kibel AS; Morgan TM; Morgans AK; Oh WK; Resnick MJ; Zietman AL; Cookson MS
J Urol; 2021 Jan; 205(1):22-29. PubMed ID: 32960678
[TBL] [Abstract][Full Text] [Related]
24. ACR Appropriateness Criteria® Definitive External-Beam Irradiation in stage T1 and T2 prostate cancer.
Nguyen PL; Aizer A; Assimos DG; D'Amico AV; Frank SJ; Gottschalk AR; Gustafson GS; Hsu IC; McLaughlin PW; Merrick G; Rosenthal SA; Showalter TN; Taira AV; Vapiwala N; Yamada Y; Davis BJ;
Am J Clin Oncol; 2014 Jun; 37(3):278-88. PubMed ID: 25180754
[TBL] [Abstract][Full Text] [Related]
25. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Jan; 65(1):124-37. PubMed ID: 24207135
[TBL] [Abstract][Full Text] [Related]
26. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
Gillessen S; Attard G; Beer TM; Beltran H; Bjartell A; Bossi A; Briganti A; Bristow RG; Chi KN; Clarke N; Davis ID; de Bono J; Drake CG; Duran I; Eeles R; Efstathiou E; Evans CP; Fanti S; Feng FY; Fizazi K; Frydenberg M; Gleave M; Halabi S; Heidenreich A; Heinrich D; Higano CTS; Hofman MS; Hussain M; James N; Kanesvaran R; Kantoff P; Khauli RB; Leibowitz R; Logothetis C; Maluf F; Millman R; Morgans AK; Morris MJ; Mottet N; Mrabti H; Murphy DG; Murthy V; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Reiter RE; Roach M; Rubin M; Ryan CJ; Saad F; Sade JP; Sartor O; Scher HI; Shore N; Small E; Smith M; Soule H; Sternberg CN; Steuber T; Suzuki H; Sweeney C; Sydes MR; Taplin ME; Tombal B; Türkeri L; van Oort I; Zapatero A; Omlin A
Eur Urol; 2020 Apr; 77(4):508-547. PubMed ID: 32001144
[TBL] [Abstract][Full Text] [Related]
27. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.
Gillessen S; Bossi A; Davis ID; de Bono J; Fizazi K; James ND; Mottet N; Shore N; Small E; Smith M; Sweeney C; Tombal B; Antonarakis ES; Aparicio AM; Armstrong AJ; Attard G; Beer TM; Beltran H; Bjartell A; Blanchard P; Briganti A; Bristow RG; Bulbul M; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Chowdhury S; Clarke CS; Clarke N; Daugaard G; De Santis M; Duran I; Eeles R; Efstathiou E; Efstathiou J; Ngozi Ekeke O; Evans CP; Fanti S; Feng FY; Fonteyne V; Fossati N; Frydenberg M; George D; Gleave M; Gravis G; Halabi S; Heinrich D; Herrmann K; Higano C; Hofman MS; Horvath LG; Hussain M; Jereczek-Fossa BA; Jones R; Kanesvaran R; Kellokumpu-Lehtinen PL; Khauli RB; Klotz L; Kramer G; Leibowitz R; Logothetis CJ; Mahal BA; Maluf F; Mateo J; Matheson D; Mehra N; Merseburger A; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Pezaro C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Rubin MA; Ryan CJ; Saad F; Pablo Sade J; Sartor OA; Scher HI; Sharifi N; Skoneczna I; Soule H; Spratt DE; Srinivas S; Sternberg CN; Steuber T; Suzuki H; Sydes MR; Taplin ME; Tilki D; Türkeri L; Turco F; Uemura H; Uemura H; Ürün Y; Vale CL; van Oort I; Vapiwala N; Walz J; Yamoah K; Ye D; Yu EY; Zapatero A; Zilli T; Omlin A
Eur Urol; 2023 Mar; 83(3):267-293. PubMed ID: 36494221
[TBL] [Abstract][Full Text] [Related]
28. Prostate specific antigen only progression of prostate cancer.
Moul JW
J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
[TBL] [Abstract][Full Text] [Related]
29. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant radiation therapy in locally advanced non-small cell lung cancer: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline.
Rodrigues G; Choy H; Bradley J; Rosenzweig KE; Bogart J; Curran WJ; Gore E; Langer C; Louie AV; Lutz S; Machtay M; Puri V; Werner-Wasik M; Videtic GMM
Pract Radiat Oncol; 2015; 5(3):149-155. PubMed ID: 25957185
[TBL] [Abstract][Full Text] [Related]
31. ACR Appropriateness Criteria® definitive external beam irradiation in stage T1 and T2 prostate cancer.
Moran BJ; DeRose P; Hsu IC; Abdel-Wahab M; Arterbery VE; Ciezki JP; Frank SJ; Mohler JL; Rosenthal SA; Rossi CJ; Yamada Y; Merrick GS
Am J Clin Oncol; 2011 Dec; 34(6):636-47. PubMed ID: 22101389
[TBL] [Abstract][Full Text] [Related]
32. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
33. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.
Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H
J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902
[TBL] [Abstract][Full Text] [Related]
34. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
Stroup SP; Cullen J; Auge BK; L'Esperance JO; Kang SK
Cancer; 2007 Sep; 110(5):1003-9. PubMed ID: 17614338
[TBL] [Abstract][Full Text] [Related]
35. Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline.
Wo JY; Anker CJ; Ashman JB; Bhadkamkar NA; Bradfield L; Chang DT; Dorth J; Garcia-Aguilar J; Goff D; Jacqmin D; Kelly P; Newman NB; Olsen J; Raldow AC; Ruiz-Garcia E; Stitzenberg KB; Thomas CR; Wu QJ; Das P
Pract Radiat Oncol; 2021; 11(1):13-25. PubMed ID: 33097436
[TBL] [Abstract][Full Text] [Related]
36. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.
Videtic GMM; Donington J; Giuliani M; Heinzerling J; Karas TZ; Kelsey CR; Lally BE; Latzka K; Lo SS; Moghanaki D; Movsas B; Rimner A; Roach M; Rodrigues G; Shirvani SM; Simone CB; Timmerman R; Daly ME
Pract Radiat Oncol; 2017; 7(5):295-301. PubMed ID: 28596092
[TBL] [Abstract][Full Text] [Related]
37. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Halasz LM; Attia A; Bradfield L; Brat DJ; Kirkpatrick JP; Laack NN; Lalani N; Lebow ES; Liu AK; Niemeier HM; Palmer JD; Peters KB; Sheehan J; Thomas RP; Vora SA; Wahl DR; Weiss SE; Yeboa DN; Zhong J; Shih HA
Pract Radiat Oncol; 2022; 12(5):370-386. PubMed ID: 35902341
[TBL] [Abstract][Full Text] [Related]
38. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy.
Do T; Parker RG; Do C; Tran L; Do L; Dolkar D
Cancer J Sci Am; 1998; 4(5):324-30. PubMed ID: 9815297
[TBL] [Abstract][Full Text] [Related]
39. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
40. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR.
Rosenkrantz AB; Verma S; Choyke P; Eberhardt SC; Eggener SE; Gaitonde K; Haider MA; Margolis DJ; Marks LS; Pinto P; Sonn GA; Taneja SS
J Urol; 2016 Dec; 196(6):1613-1618. PubMed ID: 27320841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
